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Introduction
In a recent court case in New Jersey, a jury awarded $12.9 million to three patients who were diagnosed with inflammatory bowel disease (IBD) after being treated with the acne medication isotretinoin (Accutane®, Amnesteem®, Sotret®, Claravis®). A number of similar multimillion-dollar lawsuits preceded this one. Isotretinoin was approved in 1982 by the US Food and Drug Administration (FDA) for the treatment of severe recalcitrant nodular acne by Roche. Subsequently, a number of case reports of this association were published in the postmarketing period (1) (2) (3) (4) (5) (6) , and the development of IBD was subsequently listed as a warning in the package insert for Accutane (7) . In addition to individual case reports, Reddy et al. have recently published a review of the FDA MedWatch reports of IBD cases occurring in association with isotretinoin use (8) . Although the possibility that isotretinoin may predispose to the development of IBD is a cause for serious concern, the published case reports and case series, as well as related court decisions, must be interpreted with caution.
Case reports are essential in identifying possible adverse drug reactions and are thus "hypothesis generating." However, such reports are subject to a number of flaws, including recall bias, publication bias, incomplete and subjective presentation of case details (by both patients and physicians), and lack of follow-up. Because of such biases, case reports may lead readers to assume causation and to overestimate the risks in similar patients and the population at large.
In order to evaluate whether the reported association between isotretinoin and IBD is causal, we first searched the published literature to identify all relevant papers and case reports. Next, we performed a critical appraisal of this literature using the criteria developed by Sir Austin Bradford Hill Despite the incomplete data, it is instructive to estimate the strength of this potential association using population-based estimates of isotretinoin use and IBD incidence to complete the missing cells of a traditional 2x2 table ( Table 2 ). Assuming that (i) the background incidence of IBD in the United States is approximately 45,000 cases per year (17, 18) , (ii) the number of people taking isotretinoin is approximately 400,000 per year (19) , and (iii) the total US population is approximately 306 million (20) , the expected number of cases of IBD among isotretinoin users would be 59 cases per year (if there were no association between isotretinoin and IBD), or 0.01% of isotretinoin users. If more than 59 cases per year were observed in isotretinoin users, this would suggest a positive relationship between isotretinoin use and IBD. However, FDA MedWatch reports include an average of only 14 cases per year (8) . Although MedWatch reports are certainly subject to underreporting (21) , the published number of cases does not support a strong association. Importantly, this exercise demonstrates that a certain number of cases of IBD are likely to develop in isotretinoin users simply on the basis of chance. It is possible, therefore, that the cases reported in the literature might simply be reflecting the chance coincidence of IBD and isotretinoin.
If isotretinoin use is more common in IBD sufferers, that would also contribute to the strength of the association. Although no case-control studies have been performed evaluate whether the relationship between two factors might be causal. The Hill criteria, established in 1965, comprise nine components: strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experimental evidence, and analogy (9) . Although the presence or absence of any one criterion is insufficient to confirm or refute causality, when an association fulfills a preponderance of these criteria, a case for an etiological connection can be made.
Summary of case reports
Twelve case reports (1-6,10-15) and one case series (16) were identified via a systematic search strategy. Results are summarized in Table 1 . In total, 15 cases were reported in seven countries over a 23-year period (1986 to 2008). In addition, 85 cases were reported in the FDA MedWatch analysis from 1997 to 2002 (8) . Cases developed at a range of doses (20-80 mg per day), and several of the cases were diagnosed after therapy with isotretinoin had been discontinued (2, 5, 14, 16) . Two cases resolved after isotretinoin was discontinued (12, 15) . Five of the individual case reports did not report a definitive diagnosis of IBD (11) (12) (13) (14) (15) .
Causal criteria
Strength. Strength is defined by the size of the association as measured by appropriate effect measures (risk difference, relative risk, odds ratio, or equivalent). The stronger the association, the more likely a relationship is causal. No published observational or interventional studies have adequately measured the strength of the association between isotretinoin and IBD in a quantitative way.
Case reports and case series include only individuals that had both the exposure (isotretinoin) and the outcome the time period at risk is 1 year. equal rates of ibD in both exposed people ("received isotretinoin") and unexposed people ("no isotretinoin") would correspond to an incidence rate ratio of 1 (i.e., no causation). We made assumptions about the annual incidence of ibD, the number of people exposed to isotretinoin per year, and the size of the uS population using the best available data. We then calculated the expected number of new cases of ibD per year in those taking isotretinoin assuming no causation (calculation below). the number of cases per year in those taking isotretinoin would need to be greater than 59 to support a causal association. ibD, inflammatory bowel disease; py, patient-years.
Where x = expected cases with exposure, incidence rate ratio = 1 = expected cases with exposure (x) = = 59
x / 400,000 (400,000 x) / (305,600) 45,000 × 400,000 306,000,000
with comparable frequency. It is well recognized that Crohn's disease and ulcerative colitis are distinct clinical entities that differ with respect to disease activity, pathology, and (presumably) etiopathogenesis. Other forms of colitis have also been reported, including granulomatous colitis (13) and collagenous colitis (14) . The fact that one exposure has been linked to several outcomes indicates lack of specificity. Nevertheless, specificity is considered the weakest of all the Hill criteria.
Indeed, tobacco has been demonstrated to cause a number of diseases, and illnesses such as lung cancer have multiple predisposing factors in addition to smoking. Thus, the absence of specificity does not preclude a causal relationship.
examining this relationship, one retrospective study of 306 IBD cases in Italy failed to demonstrate any prior exposures to isotretinoin (22) .
Consistency. Consistency refers to whether the observed association has been repeatedly observed in different people and different settings. For example, at the time that Hill established these criteria, there were a total of 29 retrospective and 7 prospective reports describing the association between smoking and lung cancer, each reaching the same conclusion irrespective of study design. Consistency provides reassurance that the association is not due to chance or systematic bias. Although multiple case reports of this association have been published in various geographic areas, a consistent pattern of disease occurrence has not emerged. Case reports differ with regard to duration of treatment, lag time between initiation of treatment and development of disease, whether symptoms developed on or off therapy, and clinical features of disease. However, as is discussed above, the association between isotretinoin and IBD has not been adequately measured in any studies; therefore, consistency of effect measures is impossible to establish at this time.
Specificity. Specificity refers to whether an exposure leads to a specific outcome. For example, the link between the diet-drug combination phentermine/fenfluramine and valvular heart disease in young women fulfills this criterion. In contrast, isotretinoin has protean effects (23), including teratogenicity, effects on bone mineral density, hearing and visual disturbances, and depression.
Furthermore, both Crohn's disease and ulcerative colitis have been reported in connection with this association, criterion, with higher doses corresponding to worsened risk of liver failure. Evidence of a biological gradient is supported by three cases of people who were diagnosed with IBD shortly after increasing their dose of isotretinoin (8, 12, 13) . However, there are also case reports of this association in people taking relatively low doses of isotretinoin (20 mg per day (6) and 30 mg per day (3)), as well as in patients who had discontinued isotretinoin before the presentation of IBD (2, 5, 14, 16) . Interestingly, an early study of isotretinoin's adverse effects demonstrated an inverse dose-response relationship with regard to gastrointestinal symptoms (23) . Therefore, at this time, the evidence of a biological gradient is inconclusive.
Plausibility. "Plausibility" refers to whether the observed association is biologically plausible. Given that the etiology of IBD is largely unknown, it is difficult to assess the plausibility of isotretinoin as a trigger of IBD. In fact, the mechanistic studies that are available in the published literature could support a beneficial effect of vitamin A derivatives in regard to the development and perpetuation of IBD. For example, a key factor implicated in the pathogenesis of IBD is impaired barrier function of the intestinal epithelium. Retinoic acid, a form of vitamin A, has been shown to enhance barrier function by increasing expression of numerous tight junction proteins, such as occludin, claudin-1, claudin-4, and zonula occludens-1 (26) . Furthermore, from the standpoint of immune function, retinoic acid has been shown to be capable of inhibiting proinflammatory interleukin-17-producing T-helper cell (Th17) responses, while augmenting induction of anti-inflammatory regulatory T cells (27) . Such responses would be more likely to prevent the development of IBD, as opposed to triggering it. Nevertheless, retinoids have pleiotropic effects, including natural killer T-cell stimulation, B-cell differentiation, disruption of glycoprotein synthesis and epithelial tissue growth, apoptosis, and alteration of cytokines (12, 28, 29) . Therefore, although speculative, the association between isotretinoin and IBD remains biologically plausible, although beneficial effects could be postulated as well.
Coherence. This principle states that a causal relationship should not contradict the known facts of the natural history and biology of the disease in question. One threat to coherence is that several reports have been published of use of isotretinoin in patients with known preexisting IBD who did not experience exacerbations of disease (30) (31) (32) (33) (34) (35) ; if isotretinoin causes IBD, we might expect that exposure could also lead to flares of known disease. Furthermore, although the number of prescriptions for isotretinoin in the United States rose rapidly in the 1990s (19) , rates of IBD have remained relatively constant during the same time period (18, 36) . However, as there are many unknowns regarding the etiology and pathophysiology of IBD, a causal association would be difficult to refute on the basis of lack of coherence.
Experimental evidence. This criterion refers to whether evidence in humans or other species exists to corroborate the connection. No human experiments have addressed this question, Temporality. In a temporal relationship, the cause (i.e., isotretinoin) must precede the outcome (i.e., onset of IBD). Such a temporal relationship supports, but does not confirm, a causal relationship. However, lack of a temporal relationship clearly refutes causality: an exposure that occurs after the onset of disease clearly did not cause the disease. Taken at face value, a temporal relationship exists between isotretinoin use and IBD onset, as evidenced by the numerous case reports and case series. However, we propose several, non-causal explanations for the observed temporal relationship. First, the association may be due to confounding based on age. The peak age of IBD occurrence is in early adulthood, and the peak age of isotretinoin use is age 13-24 years (Figure 1) (19) . Therefore, in the absence of causation, most cases of IBD developing in people who also have acne and are prescribed isotretinoin will occur in this order.
In addition, the biological onset of IBD and initial symptoms often occur 1 year (or longer) before diagnosis. Therefore, as has been suggested by other authors (6, 8) , it is possible in some cases that although the disease diagnosis may have occurred after exposure to isotretinoin, the disease onset may actually have preceded isotretinoin therapy (i.e., isotretinoin was given to people with subclinical IBD) (Figure 2) . We must also consider the possibility of reverse causation: that IBD resulted in exposure to isotretinoin. Pyoderma faciale is a dermatological condition that may mimic severe acne but is in fact a known extraintestinal manifestation of IBD that may precede its diagnosis (Figure 3) (24) . Neutrophilic dermatoses such as Sweet's syndrome may also be associated with IBD (25) . It is possible that some cases of this association occur in patients whose underlying IBD (as manifested by these acne-like skin conditions) preceded isotretinoin use, and thus the observed temporal relationship was inverted.
Another component of temporality is whether the adverse event abates after withdrawal of medication and recurs with reintroduction of medication. This pattern has been observed in some case reports (12) ; however, it is difficult to interpret for a relapsing and remitting condition such as IBD. The natural course of the disease may be mistaken for results of reintroduction and withdrawal of isotretinoin. Also, the observation that symptoms resolve upon discontinuation of isotretinoin therapy, in most cases, would be complicated by concomitant initiation of IBD therapy (e.g., corticosteroids), another example of confounding. Furthermore, the observation that symptoms return upon reintroduction of isotretinoin is complicated by the fact that reintroduction is likely to occur during periods of disease remission. On the basis of the natural history of the disease itself, independent of any effects of isotretinoin, some of these patients will experience a recurrence of symptoms (Figure 2) . Biological gradient. The biological gradient criterion refers to whether a dose-response relationship is present: if an increasing dose of the exposure corresponds to an increase in incidence and/or severity of effects, this supports a causal relationship. For example, acetaminophen-induced hepatotoxicity fulfills this and we were unable to find published evidence of colitis developing in animals exposed to isotretinoin or similar compounds. Experimental evidence also refers to whether the outcome can be prevented or ameliorated by an appropriate experimental regimen. Because the mechanisms of isotretinoin are largely unknown and no single "antidote" exists, such experiments are not possible.
Analogy. Analogy refers to the effect of similar factors. There are no known medication triggers of IBD from which to draw analogies, and no other retinoid compounds have been linked to IBD. Nor can analogies be drawn from isotretinoin's proposed mechanisms of acne amelioration (inhibition of sebaceous gland function and keratinization) (37) and teratogenicity (impaired cephalic neural-crest-cell activity) (38) , which seem distinct from the putative mechanisms of IBD, which involves disruption of bowel mucosa integrity and induction of autoimmunity.
Conclusion
In conclusion, the only evidence to support a causal association between isotretinoin and IBD consists of isolated case reports. These reports support a possible temporal association between isotretinoin and the development of IBD, although such observations may have resulted from chance, confounding, bias, and misrepresentation of the natural history of IBD. A causal relationship remains biologically plausible, but beneficial effects of vitamin A derivatives on intestinal injury have been reported as well. None of the other commonly accepted causal criteria are met. The lack of evidence does not necessarily indicate lack of a causal connection. However, in the absence of observational studies that assess the strength and consistency of the association and/or experimental studies that confirm such an association, any conclusions about a causal link are premature at best, and future studies are needed to enable a more rigorous assessment about causality. Until that becomes possible, it is difficult to provide any substantive assessment of the IBD-associated risks of isotretinoin use. Therefore, although it remains possible that an association between isotretinoin and IBD will eventually be established, current published evidence is insufficient to support this claim.
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